Agilent Technologies (NYSE:A) Price Target Cut to $165.00 by Analysts at HSBC

Agilent Technologies (NYSE:A) had its price target reduced by HSBC from $180.00 to $165.00 in a report issued on Wednesday,Benzinga reports. HSBC currently has a buy rating on the medical research company’s stock.

Several other research analysts have also commented on the company. Royal Bank Of Canada initiated coverage on Agilent Technologies in a research report on Wednesday, May 27th. They issued an “outperform” rating and a $153.00 price target for the company. Wolfe Research restated a “hold” rating on shares of Agilent Technologies in a research report on Tuesday. Bank of America upgraded Agilent Technologies from a “neutral” rating to a “buy” rating and dropped their target price for the company from $150.00 to $145.00 in a research report on Thursday, May 28th. Morgan Stanley dropped their target price on Agilent Technologies from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Finally, Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, May 30th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $161.71.

Agilent Technologies Trading Up 2.2%

A opened at $138.01 on Wednesday. The firm has a market cap of $38.98 billion, a P/E ratio of 27.71, a P/E/G ratio of 2.41 and a beta of 1.26. Agilent Technologies has a 12 month low of $108.35 and a 12 month high of $160.27. The company has a current ratio of 2.10, a quick ratio of 1.62 and a debt-to-equity ratio of 0.43. The stock has a 50-day moving average of $117.41 and a 200 day moving average of $128.36.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, May 27th. The medical research company reported $1.49 EPS for the quarter, topping the consensus estimate of $1.41 by $0.08. The company had revenue of $1.84 billion during the quarter, compared to analyst estimates of $1.80 billion. Agilent Technologies had a return on equity of 24.33% and a net margin of 19.55%.The firm’s revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the business posted $1.31 earnings per share. Agilent Technologies has set its FY 2026 guidance at 6.000-6.100 EPS and its Q3 2026 guidance at 1.480-1.500 EPS. As a group, research analysts forecast that Agilent Technologies will post 5.99 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Tuesday, June 30th will be given a dividend of $0.255 per share. This represents a $1.02 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Tuesday, June 30th. Agilent Technologies’s payout ratio is 20.48%.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA raised its stake in shares of Agilent Technologies by 13.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 14,147,601 shares of the medical research company’s stock valued at $1,925,064,000 after acquiring an additional 1,713,216 shares in the last quarter. State Street Corp raised its stake in shares of Agilent Technologies by 1.9% during the fourth quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock valued at $1,725,611,000 after acquiring an additional 241,029 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Agilent Technologies by 4.8% during the third quarter. Wellington Management Group LLP now owns 9,380,521 shares of the medical research company’s stock valued at $1,203,990,000 after acquiring an additional 433,342 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Agilent Technologies by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 7,425,861 shares of the medical research company’s stock valued at $1,006,519,000 after acquiring an additional 25,139 shares in the last quarter. Finally, Generation Investment Management LLP raised its stake in shares of Agilent Technologies by 10.1% during the third quarter. Generation Investment Management LLP now owns 6,357,953 shares of the medical research company’s stock valued at $816,043,000 after acquiring an additional 582,093 shares in the last quarter.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.